OVERVIEW

Community Practice Connections™: Optimizing Outcomes in Melanoma with BRAF/MEK Inhibitor and Immunotherapeutic Strategies: Essentials for the Onco-Nurse is organized by Physicians' Education Resource, LLC (PER).

Release Date: June 30, 2019
Expiration Date: June 30, 2020

Target Audience:
This educational program is directed toward oncology nurses and other oncology healthcare professionals who participate in the multidisciplinary treatment and management of patients with melanoma.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Activity Overview:
In this program, physicians Omid Hamid, MD, and Geoffrey T. Gibney, MD, presented best practices in the management of melanoma with nurses Grace Cherry, RN, MSN, NP, and Krista M. Rubin, MS, FNP-BC. Participants shared clinical data underlying treatment decisions that are commonly made in advanced melanoma, including the choice of adjuvant therapy and treatment using BRAF/MEK inhibitors and checkpoint inhibitors in selected patients. Participants also discussed the importance of interprofessional collaboration in educating patients on potential adverse events (AEs) and managing AEs across melanoma. Treatment strategies in development, including combination BRAF/MEK inhibition and checkpoint inhibition, are also discussed in this program, as well as early data from combination clinical trials.

Learning Objectives:
Upon successful completion of this educational program, you should be better prepared to:
• Outline the mechanistic rationale and recent evidence on evolving BRAF/MEK inhibition and immunotherapeutic strategies for melanoma management.
• Consider the clinical significance of practice-changing datasets concerning BRAF/MEK inhibition and immunotherapeutic strategies, and their application in the treatment of patients with melanoma.
• Apply best practices to proactively identify and mitigate the impact of treatment-related toxicities in settings in which patients with melanoma are managed.
• Evaluate nursing opportunities to optimize counseling in the setting of melanoma to manage treatment-related toxicities.

Additional details will be posted as soon as information is available.